These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28053071)

  • 41. Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes.
    Soyars CL; Peterson BA; Burr CA; Nimchuk ZL
    Plant Cell Physiol; 2018 Aug; 59(8):1608-1620. PubMed ID: 29912402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No off-target mutations in functional genome regions of a CRISPR/Cas9-generated monkey model of muscular dystrophy.
    Wang S; Ren S; Bai R; Xiao P; Zhou Q; Zhou Y; Zhou Z; Niu Y; Ji W; Chen Y
    J Biol Chem; 2018 Jul; 293(30):11654-11658. PubMed ID: 29941452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery.
    Khurana A; Sayed N; Singh V; Khurana I; Allawadhi P; Rawat PS; Navik U; Pasumarthi SK; Bharani KK; Weiskirchen R
    J Cell Biochem; 2022 Oct; 123(10):1674-1698. PubMed ID: 36128934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRISPR genome engineering for retinal diseases.
    Kantor A; McClements ME; Peddle CF; Fry LE; Salman A; Cehajic-Kapetanovic J; Xue K; MacLaren RE
    Prog Mol Biol Transl Sci; 2021; 182():29-79. PubMed ID: 34175046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.
    Wang Y; Wang S; Chen W; Song L; Zhang Y; Shen Z; Yu F; Li M; Ji Q
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217854
    [No Abstract]   [Full Text] [Related]  

  • 46. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR therapeutic tools for complex genetic disorders and cancer (Review).
    Baliou S; Adamaki M; Kyriakopoulos AM; Spandidos DA; Panayiotidis M; Christodoulou I; Zoumpourlis V
    Int J Oncol; 2018 Aug; 53(2):443-468. PubMed ID: 29901119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of CRISPR/Cas Systems for Precise Genome Editing.
    Hryhorowicz M; Lipiński D; Zeyland J
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy.
    Chandrasekaran AP; Karapurkar JK; Chung HY; Ramakrishna S
    Biotechnol J; 2022 Jul; 17(7):e2100468. PubMed ID: 35157790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Precision genome editing in plants: state-of-the-art in CRISPR/Cas9-based genome engineering.
    Wada N; Ueta R; Osakabe Y; Osakabe K
    BMC Plant Biol; 2020 May; 20(1):234. PubMed ID: 32450802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A beginner's guide to gene editing.
    Harrison PT; Hart S
    Exp Physiol; 2018 Apr; 103(4):439-448. PubMed ID: 29282799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic and diagnostic relevance of Crispr technology.
    El Ouar I; Djekoun A
    Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
    Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
    Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.